British pharmaceutical group GlaxoSmithKline and German biotech firm CureVac on Wednesday announced plans to jointly develop a coronavirus vaccine with the potential to counter multi-variants of the virus that causes Covid-19. “The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval,” a joint statement said. GSK will also support the manufacture this year of up to 100 million doses of CureVac’s first generation Covid-19 vaccine, it added. The collaboration, building on an existing relationship, is to develop next generation Covid-19 vaccines “with the potential for a multi-valent approach to address mult
Hence then, the article about gsk curevac to develop vaccine against coronavirus variants was published today ( ) and is available onsamanews ( palestine ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( GSK, CureVac to develop vaccine against coronavirus variants )